Apollo Endosurgery

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apollo Endosurgery develops medical devices for the diagnosis and treatment of gastrointestinal diseases. The company’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon. Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.)  Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.

AUSTIN, TX / ACCESSWWIRE / June 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that management will participate in two investor conference events during the month of June 2021. Conferences Apollo Endosurgery management will participate include: Wednesday, June 2, 2021 18th Annual Craig-Hallum Institutional Investor Conference Management will host one-on-one virtual meetings for institutional investors Wednesday, June 16 and Thursday, June 17, 2021 JMP Securities Life Sciences Conference Management will lead a group presentation at 3:30 pm Eastern Time on Thursday June 17 One-on-one virtual meetings available will be available for institutional investors For more information about scheduling a one-on-one meeting with management, please contact a Craig-Hallum or JMP Securities institutional sales representative or Matt Kreps, Investor Relations for Apollo Endosurgery, at mkreps@darrowir.com.

Apollo Endosurgery to Present at June Investor Conferences

AUSTIN, TX / ACCESSWIRE / May 24, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced highlights from Digestive Disease Week (DDW) 2021 which was held May 21-23. During the 3-day virtual event, there were more than 30 different presentations featuring the use of the OverStitch™ Endoscopic Suturing System in a variety of endoscopic procedures.

Apollo Endosurgery's Innovative OverStitch(TM) Endoscopic Suturing System Highlighted During Digestive Disease Week 2021

AUSTIN, TX / ACCESSWIRE / May 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the Sidoti & Company Virtual Microcap Conference on May 20, 2021. Management will present an overview presentation on Thursday, May 20, at 10:00 am Eastern Standard Time.

Apollo Endosurgery to Present at Sidoti Conference May 20

Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q1 2021 Results - Earnings Call Transcript

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m.

Apollo Endosurgery, Inc. Reports 29% Increase in First Quarter Revenue

The stock price of Apollo Endosurgery Inc (NASDAQ: APEN) increased from $5.59 to $5.81 pre-market. This is why it happened.

APEN Stock: From $5.59 To $5.81 (3.94% Increase) Pre-Market Explanation

Kirk Ellis to Serve as Vice President of US Sales Steve Bosrock to Serve as Vice President of Marketing & Medical Education AUSTIN, TX / ACCESSWIRE / May 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointments of Kirk Ellis as Vice President of US Sales and Steve Bosrock as Vice President of Marketing & Medical Education. Splitting the Vice President of Marketing and Sales into two roles will enhance Apollo's commercial acumen as the company pursues attractive growth prospects across three product lines.

Apollo Endosurgery Announces Appointments to Commercial Leadership Team

AUSTIN, TX / ACCESSWIRE / April 28, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after the market closes. In conjunction with the release, Apollo will host a conference call at 3:30 p.m.

Apollo Endosurgery to Report First Quarter Financial Results on May 4, 2021

Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Apollo Endosurgery, Inc. (APEN) Report Negative Q1 Earnings? What You Should Know

Authors conclude, " Compared to TTS clip, X-Tack is superior for effecting large mucosal defect closure, including durable sealing of full-thickness perforation. " AUSTIN, TX / ACCESSWIRE / April 21, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the publication of supporting pre-clinical results for the X-Tack™ Endoscopic HeliX Tacking System.

Apollo Endosurgery Announces Publication of Pre-Clinical Results for X-Tack(TM) Endoscopic HeliX Tacking System

AUSTIN, TX / ACCESSWIRE / March 19, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the terms of equity awards granted to Chas McKhann in connection with his appointment as the company's CEO in March 2021. The company's board of directors granted Chas a stock option to purchase an aggregate of 848,733 shares of common stock, at a per share exercise price of $5.95, and a performance-based restricted stock unit award for 707,278 shares of common stock.

Apollo Endosurgery Announces Inducement Grant

AUSTIN, TX / ACCESSWIRE / March 8, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the assignment of Category I Current Procedural Terminology (CPT®) codes with short form descriptor esophagogastroduodenoscopy with deployment of gastric bariatric device (e.g., balloon) under endoscopic guidance.

Apollo Endosurgery announces AMA assignment of Category I CPT Codes for use in Intragastric Balloon Procedures

AUSTIN, TX / ACCESSWIRE / March 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will participate in the H.C. Wainwright Global Life Sciences Conference taking place virtually March 9-10, 2021.

Apollo Endosurgery to Present at HC Wainwright Global Life Sciences Conference

The stock price of Apollo Endosurgery Inc (NASDAQ: APEN) is trading at over 55% pre-market. This is why it happened.

APEN Stock Price Increases Over 55% Pre-Market: Why It Happened

AUSTIN, TX / ACCESSWIRE / March 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has received a Breakthrough Device Designation from the U.S. Food and Drug Administration for the Orbera® Intragastric Balloon, specifically for the indication for use in treating patients with BMI between 30-40 kg/m2 with noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis. The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

Apollo Endosurgery Receives FDA Breakthrough Device Designation for the Orbera(R) Intragastric Balloon for Treatment of Patients with NASH

Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q4 2020 Results - Earnings Call Transcript

Apollo Endosurgery (NASDAQ:APEN) announces its next round of earnings this Thursday, February 25. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.

Apollo Endosurgery's Earnings: A Preview

AUSTIN, TX / ACCESSWIRE / January 5, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021.

Apollo Endosurgery to Present at HC Wainwright Bioconnect Conference

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- URGENT: SHAREHOLDER VOTE OCTOBER 7, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apollo Endosurgery, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q1 2020 Results - Earnings Call Transcript

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares U.S. Real Estate ETF

iShares Transportation Average ETF

Consumer Staples Select Sector SPDR Fund

Beyond Meat

Ramco-Gershenson Properties

Tenet Healthcare

The annual U.S. inflation for the month of November beat expectations and put these ETFs and stocks in focus.

5 ETFs & Stocks to Profit From One-Year High U.S. Inflation

Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q3 2019 Results - Earnings Call Transcript

Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q2 2019 Results - Earnings Call Transcript

Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q1 2019 Results - Earnings Call Transcript

Apollo Endosurgery (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Apollo Endosurgery Stock (APEN)